EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix

Patrick Campbell iD, Georges Gebrael, Arshit Narang, Chadi Hage Chehade, Vinay Mathew Thomas, Gliceida Galarza Fortuna, Nicolas Sayegh, Nishita Tripathi, Clara Tandar, Emre Dal, Haoran Li, Umang Swami und 2 weitere

Therapeutic Advances in Urology · 2024-01 · 16

DOI: 10.1177/17562872241293779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Urology, online erschienen am 08.11.2024. Verfasst von Patrick Campbell und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives: Intermittent androgen deprivation therapy (iADT) may result in measurable improvements in quality of life over continuous ADT in patients with advanced prostate cancer (aPC). Here, we studied time to castration and testosterone recovery in real-world patients with aPC undergoing iADT with relugolix. Methods and design: Eligibility criteria for this retrospective study were histologically confirmed through the diagnosis of aPC and initiation of iADT with relugolix. Primary endpoints were time to castrate level of testosterone after relugolix initiation and time to recovery to noncastrate levels after relugolix discontinuation. Results: Overall, 25 patients with aPC were treated with iADT and with relugolix. Median time to serum testosterone 50 ng/dL was 1.4 months [range 0.83–6.57 months] from holding treatment with relugolix. Conclusion: iADT with relugolix is associated with a rapid time to testosterone suppression and recovery. These results may guide patients’ counseling and monitoring of serum testosterone and PSA levels in patients wishing to pursue iADT for aPC.

Schlagwörter

Stichwörter der Autor:innen

Regulolixadvanced prostate cancerintermittent ADT

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Internal Medicine, Detroit Medical Center Sinai Grace Hospital, Detroit, MI, USA.
  • Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS, USA.
  • Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

ORCID-Profile: Patrick Campbell

Zitieren

APA

Campbell, P., Gebrael, G., Narang, A., Chehade, C. H., Thomas, V. M., Galarza Fortuna, G., Sayegh, N., Tripathi, N., Tandar, C., Dal, E., Li, H., Swami, U., Agarwal, N., & Maughan, B. L. (2024). Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. Therapeutic Advances in Urology, 16. https://doi.org/10.1177/17562872241293779

Vancouver

Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, et al. Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. Therapeutic Advances in Urology. 2024;16. doi:10.1177/17562872241293779

BibTeX
@article{Campbell2024,
  author = {Campbell, Patrick and Gebrael, Georges and Narang, Arshit and Chehade, Chadi Hage and Thomas, Vinay Mathew and Galarza Fortuna, Gliceida and Sayegh, Nicolas and Tripathi, Nishita and Tandar, Clara and Dal, Emre and Li, Haoran and Swami, Umang and Agarwal, Neeraj and Maughan, Benjamin L},
  title = {Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix},
  journal = {Therapeutic Advances in Urology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17562872241293779}
}
Kostenlos starten →